TY - JOUR
T1 - Significant Reduction in the Diagnosis of Barrett’s Esophagus and Related Dysplasia During the COVID-19 Pandemic
AU - Pokala, Sridevi K.
AU - Williams, J. Lucas
AU - Holub, Jennifer L.
AU - Calderwood, Audrey H.
AU - Dominitz, Jason A.
AU - Iyer, Prasad G.
AU - Shaheen, Nicholas J.
AU - Wani, Sachin
N1 - Publisher Copyright:
© 2023 by The American College of Gastroenterology.
PY - 2024/2/1
Y1 - 2024/2/1
N2 - INTRODUCTION: The coronavirus disease 19 (COVID-19) pandemic disrupted endoscopy practices, creating unprecedented decreases in cancer screening and surveillance services. We aimed to assess the impact of the pandemic on the proportion of patients diagnosed with Barrett’s esophagus (BE) and BE-related dysplasia and adherence to established quality indicators. METHODS: Data from all esophagogastroduodenoscopies in the GI Quality Improvement Consortium, a national repository of matched endoscopy and pathology data, were analyzed from January 2018 to December 2022. Four cohorts were created based on procedure date and COVID-19 data: pre-pandemic (January 2018 to February 2020), pandemic-phase I (March 2020 to July 2020), pandemic-phase II (August 2020 to May 2021), and pandemic-phase III (June 2021 to December 2022). Observed and expected number of BE and BE-related dysplasia cases per month and adherence to the Seattle biopsy protocol and recommended surveillance intervals for nondysplastic BE (NDBE) were evaluated. RESULTS: Among 2,446,857 esophagogastroduodenoscopies performed during the study period, 104,124 (4.3%) had pathology-confirmed BE. The histologic distribution was 87.4% NDBE, 1.8% low-grade dysplasia, 2.4% indefinite for dysplasia, and 1.4% high-grade dysplasia. The number of monthly BE (247.9% pandemic-phase I, 221.5% pandemic-phase II, and 219.0% pandemic-phase III) and BE-related dysplasia (high-grade dysplasia: 41.2%, 227.7%, and 219.0%; low-grade dysplasia: 49.1%, 235.3%, and 226.5%; any dysplasia: 46.7%, 232.3%, and 227.9%) diagnoses were significantly reduced during the pandemic phases compared with pre-pandemic data. Adherence rates to the Seattle protocol and recommended surveillance intervals for NDBE did not decline during the pandemic. DISCUSSION: There was a significant decline in the number of BE and BE-related dysplasia diagnoses during the COVID-19 pandemic, with an approximately 50% reduction in the number of cases of dysplasia diagnosed in the early pandemic. The absence of a compensatory increase in diagnoses in the pandemic-phase II and III periods may result in deleterious downstream effects on esophageal adenocarcinoma morbidity and mortality.
AB - INTRODUCTION: The coronavirus disease 19 (COVID-19) pandemic disrupted endoscopy practices, creating unprecedented decreases in cancer screening and surveillance services. We aimed to assess the impact of the pandemic on the proportion of patients diagnosed with Barrett’s esophagus (BE) and BE-related dysplasia and adherence to established quality indicators. METHODS: Data from all esophagogastroduodenoscopies in the GI Quality Improvement Consortium, a national repository of matched endoscopy and pathology data, were analyzed from January 2018 to December 2022. Four cohorts were created based on procedure date and COVID-19 data: pre-pandemic (January 2018 to February 2020), pandemic-phase I (March 2020 to July 2020), pandemic-phase II (August 2020 to May 2021), and pandemic-phase III (June 2021 to December 2022). Observed and expected number of BE and BE-related dysplasia cases per month and adherence to the Seattle biopsy protocol and recommended surveillance intervals for nondysplastic BE (NDBE) were evaluated. RESULTS: Among 2,446,857 esophagogastroduodenoscopies performed during the study period, 104,124 (4.3%) had pathology-confirmed BE. The histologic distribution was 87.4% NDBE, 1.8% low-grade dysplasia, 2.4% indefinite for dysplasia, and 1.4% high-grade dysplasia. The number of monthly BE (247.9% pandemic-phase I, 221.5% pandemic-phase II, and 219.0% pandemic-phase III) and BE-related dysplasia (high-grade dysplasia: 41.2%, 227.7%, and 219.0%; low-grade dysplasia: 49.1%, 235.3%, and 226.5%; any dysplasia: 46.7%, 232.3%, and 227.9%) diagnoses were significantly reduced during the pandemic phases compared with pre-pandemic data. Adherence rates to the Seattle protocol and recommended surveillance intervals for NDBE did not decline during the pandemic. DISCUSSION: There was a significant decline in the number of BE and BE-related dysplasia diagnoses during the COVID-19 pandemic, with an approximately 50% reduction in the number of cases of dysplasia diagnosed in the early pandemic. The absence of a compensatory increase in diagnoses in the pandemic-phase II and III periods may result in deleterious downstream effects on esophageal adenocarcinoma morbidity and mortality.
KW - Barrett’s esophagus
KW - Barrett’s esophagus-related dysplasia
KW - COVID-19 esophagogastroduodenoscopy
UR - http://www.scopus.com/inward/record.url?scp=85184285377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184285377&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000002527
DO - 10.14309/ajg.0000000000002527
M3 - Article
C2 - 37782262
AN - SCOPUS:85184285377
SN - 0002-9270
VL - 119
SP - 251
EP - 261
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 2
ER -